Stay informed with the latest litigation news. Explore now

Risperidone Sustained Release Microsphere Composition - EP3199146B1

EP3199146

NANJING LUYE PHARMACEUTICAL
Application Number
EP16179390A
Filing Date
Apr 10, 2012
Status
Opposition Rejected
Apr 2, 2022
Grant Date
Jul 17, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Bibliography

The patent EP3199146B1 was granted to Nanjing Luye Pharmaceutical on Jul 17, 2019 following the initial filing on Apr 10, 2012 under the application number EP16179390A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALKERMES PHARMA IRELANDApr 17, 2020ADMISSIBLE
AERAApr 14, 2020ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents